Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

Leukemia. 2015 Dec;29(12):2429-31. doi: 10.1038/leu.2015.274. Epub 2015 Oct 7.

¹ Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
² Azienda Policlinico Umberto I, University La Sapienza, Roma, Italy.
³ Hematology and Bone Marrow Transplant Unit, Udine, Italy.
⁴ Department of Clinical and Molecular Bio-Medicine, University of Catania, Catania, Italy.
⁵ Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.
⁶ Hematology-Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
⁷ Arcispedale S. Maria Nuova, Hematology, Reggio Emilia, Italy.
⁸ University of Torino, Azienda Ospedaliero-Universitaria (AOU) S. Giovanni Battista Torino, Torino, Italy.
⁹ Department of Hematology, Erasmus MC, Rotterdam, The Netherlands.

No abstract available

Publication types